// App-Quantinova.ai

15521 2014 AHA : Evaluation of Medical Costs Avoided When New Oral Anticoagulants Are Used for Extended Treatment of Venous Thromboembolism Based on Clinical Trial Results

Researchers

Presenter

  • Yonghua Jing

Principal Investigators

  • Jeffrey Trocio

  • Jay Lin

  • Melissa Lingohr Smith

  • John Graham

Medical Centers

  • University California, Irvine, Irvine, CA

  • Novosys Health, Flemington, NJ

Locations

  • United States

Companies

  • Pfizer Inc.

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved